Table 2 Baseline clinical characteristics of the participants
Characteristics | AT group N = 7 | TAU group N = 6 | All participants N = 13 |
|---|---|---|---|
Duration of diabetes in years | |||
 Median | 5 | 3 | 5 |
 Range | 2–20 | 2–13 | 2–20 |
HbA1c, n (%) | n = 4 | n = 3 | n = 7 |
 Normal | 2 (50) | 2 (67) | 4 (57) |
 Abnormal | 2 (50) | 1 (33) | 3 (43) |
Medication measures, mean (SD) | n = 7 | n = 6 | n = 13 |
 MARS-5 | 21 (3.00) | 21.5 (2.66) | 21.23 (2.74) |
 BMQ-General | 41.14 (4.41) | 40.83 (6.18) | 41.00 (5.07) |
Diabetes complications, n (%) | n = 7 | n = 6 | n = 13 |
 Yes | 0 (0) | 1 (17) | 1 (8) |
 No | 7 (100) | 5 (83) | 12 (92) |
Comorbidity, n (%) | |||
 Yes | 5 (71) | 3 (50) | 8 (62) |
 No | 2 (29) | 3 (50) | 5 (38) |